Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $16.6652W HIGH $38.11
Volume
1.18 M
Value Traded
43.53 M
Short % Float
13.62%
+4.31%Week
-13.69%1 Month
-14.31%3 Month
-22.84%6 Month
-17.14%5 Year
-17.14%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.03 B
EPS (TTM)
-1.92
P/E Ratio
-
Ent. Value
849.00 M
Total Shares
57.27 M
Float Shares
54.63 M
Insiders
4.62%
Institutions
98.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
PRCT Catalyst Timeline
Dated clinical, regulatory and corporate events for PROCEPT BioRobotics Corporation
Past FDA Catalysts and PDUFA Decisions
How PRCT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
PROCEPT BioRobotics Corporation is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every PRCT program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Nouri AlalehOfficer (EVP, CLO, CORP. SEC.) | Sell | -297 127,737 held | $20.95 | 09/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRCT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.8 % (700 %) | 22.65 M | 1.00 M | 4,915% ( 983.00 K) |
PRCT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRCT ranks across every disease it competes in
Competitive Position is a premium feature
See how PRCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRCT News
PRCT▼ -6%on this news
LAWSUIT NOTICE: NASDAQ: PRCT Investors who lost money with PROCEPT BioRobotics Corporation shares should contact the Shareholders Foundation
A lawsuit has been filed against PROCEPT BioRobotics Corporation by an investor alleging violations of securities laws. The plaintiff claims the company misrepresented its sales figures by using a discount program that incentivized bulk orders beyond demand. This practice reportedly led to overstocking and exposed the company to significant financial risks.
Read more →PRCTPROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026
PROCEPT BioRobotics Corporation will participate in the Baird 2026 Global Healthcare Conference on September 15, 2026. Management will present and host investor meetings in New York City. The company focuses on surgical robotics and has developed the AQUABEAM and HYDROS Robotic Systems for urology treatments, particularly for BPH.
Read more →PRCT▲ +5.8%on this news· ran to +19% by day 3
PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results
PROCEPT BioRobotics reported a strong second quarter for 2026, with a 19% increase in revenue driven by higher U.S. procedure volumes and system placements. The company achieved record placements of its HYDROS systems and received favorable updates in clinical guidelines for Aquablation therapy. However, the net loss increased, reflecting higher operating expenses related to growth initiatives.
Read more →PRCTPROCEPT BioRobotics® to Report Second Quarter 2026 Financial Results on August 4th, 2026
PROCEPT BioRobotics Corporation announced it will report its financial results for the second quarter of 2026 on August 4, 2026. A conference call will follow the report at 4:30 p.m. Eastern Time. The company specializes in surgical robotics and has made significant advancements in urology, particularly in treating BPH.
Read more →PRCTPROCEPT BioRobotics® Advances Prostate Cancer Program with WATER IV Study Enrollment Completion and Expanded IDE Approval
PROCEPT BioRobotics has completed enrollment in its WATER IV study, which evaluates Aquablation therapy against radical prostatectomy. The company also received FDA IDE approval for a second study comparing Aquablation therapy to active surveillance. Both studies aim to assess long-term outcomes for prostate cancer patients, with results expected to be presented at the AUA Annual Meeting in 2027.
Read more →PRCT▲ +10.7%on this news
PROCEPT BioRobotics to Attend Three Upcoming Investor Conferences in May & June
PROCEPT BioRobotics will participate in three investor conferences scheduled throughout May and June 2026. The events include the Bank of America Health Care Conference in Las Vegas, the 46th Annual William Blair Growth Stock Conference in Chicago, and the Truist Med-Tech Conference in Boston. These presentations aim to showcase the company’s advancements in surgical robotics and its focus on urological care. Webcasts of the events will be available for replay on the company's website for 90 days post-event.
Read more →PRCT▼ -5.7%on this newsshared move
PROCEPT BioRobotics Reports First Quarter 2026 Financial Results
PROCEPT BioRobotics reported its first quarter 2026 financial results, showcasing a revenue growth of 20% to $83.1 million, largely due to increased U.S. system sales. The company noted a significant rise in U.S. procedures, completing approximately 12,200, marking a 30% increase from the previous year. However, operating expenses also rose, which contributed to a net loss of $31.6 million. The company has received FDA clearance for its enhanced FirstAssist AI software aimed at improving Aquablation therapy. Looking ahead, PROCEPT BioRobotics anticipates continued growth for the full year 2026, projecting revenues between $390 million to $410 million.
Read more →PRCTPROCEPT BioRobotics® to Report First Quarter 2026 Financial Results on April 29, 2026
PROCEPT BioRobotics will announce its financial results for Q1 2026 on April 29, 2026. The company specializes in surgical robotics aimed at improving urological patient care. A conference call will follow the results announcement, allowing investors to engage directly with management. The company highlights its innovative Aquablation therapy and significant clinical evidence.
Read more →PRCTEAU Guidelines Upgrade Aquablation® Therapy to Strong Surgical Recommendation for BPH
The European Association of Urology has upgraded Aquablation therapy to a strong recommendation for treating benign prostatic hyperplasia (BPH). This decision is based on robust clinical evidence demonstrating its effectiveness and safety, particularly for patients wishing to maintain ejaculatory function. The guidelines highlight the therapy's applicability across various prostate anatomies and its endorsement by health technology assessment bodies.
Read more →PRCT▼ -6%on this news
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
PROCEPT BioRobotics has announced the international launch of the HYDROS Robotic System, designed for Aquablation therapy to treat benign prostatic hyperplasia (BPH). This AI-enabled platform enhances surgical precision and personalization, offering durable symptom relief while preserving quality of life. The system is set to expand access to effective treatment options for men suffering from BPH.
Read more →PRCT▼ -15.1%on this news
PROCEPT BioRobotics® Hosts 2026 Investor Day to Detail Multi-year Financial Outlook and Strategic Plan for Long-Term Growth
PROCEPT BioRobotics hosted its 2026 Investor Day in New York, presenting its long-term growth strategy and financial outlook. The company highlighted the significant market opportunity in treating BPH and the clinical success of its Aquablation therapy. PROCEPT aims to enhance its leadership in BPH, with a focus on patient education and international expansion.
Read more →PRCT▼ -15.1%on this newsshared move
PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
PROCEPT BioRobotics reported its fourth quarter 2025 financial results, highlighting a 12% increase in total revenue year-over-year. The company achieved record procedure volumes but faced a net loss of $29.8 million. Looking ahead, PROCEPT has adjusted its 2026 revenue guidance to $390-$410 million, anticipating a growth rate of 27%-33%. The company is focusing on aligning handpiece sales with procedure volumes to drive sustainable growth.
Read more →PRCTPROCEPT BioRobotics® Announces Updated Dates for 4Q25 Earnings Conference Call and Investor Day
PROCEPT BioRobotics has announced updated dates for its fourth quarter 2025 earnings conference call and Investor Day due to travel disruptions from inclement weather. The earnings report will be released on February 25, 2026, followed by a conference call. The in-person Investor Day is rescheduled for February 26, 2026, at NASDAQ Headquarters in New York City.
Read more →PRCT▼ -5.3%on this news
PROCEPT BioRobotics® to Attend the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference
PROCEPT BioRobotics will present at the TD Cowen 46th Annual Health Care Conference and the 2026 Leerink Global Healthcare Conference in March. The company focuses on advancing urology care through its robotic solutions, including the AQUABEAM and HYDROS systems. Webcasts of the presentations will be available for replay on their website.
Read more →PRCTPROCEPT BioRobotics to Host 4Q25 Earnings Conference Call on February 24, 2026, and Investor Day on February 25, 2026, in New York City
PROCEPT BioRobotics Corporation has scheduled its fourth quarter of 2025 earnings report for February 24, 2026, followed by an investor day on February 25, 2026, in New York City. The earnings call will take place after market close, while the in-person investor event at NASDAQ Headquarters will commence in the morning. The company emphasizes its focus on transforming urology through advanced robotic solutions, particularly highlighting the AQUABEAM and HYDROS systems used in BPH treatment. Live webcasts of both events will be available on their website, ensuring accessibility for all interested parties.
Read more →PRCTPROCEPT BioRobotics to Present at Upcoming 37th Annual Piper Sandler Healthcare Conference on December 2, 2025
PROCEPT BioRobotics will present at the 37th Annual Piper Sandler Healthcare Conference in New York City on December 2, 2025. The management's participation highlights the company's commitment to advancing robotic solutions for urology, particularly in treating benign prostatic hyperplasia (BPH). The conference presentation will be accessible via a live webcast, demonstrating the company's focus on investor relations. PROCEPT BioRobotics is recognized for its innovative AQUABEAM and HYDROS robotic systems which are designed to enhance patient care outcomes.
Read more →PRCT▼ -9.7%on this news
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
PROCEPT BioRobotics reported strong financial results for Q3 2025, with total revenue reaching $83.3 million, a 43% increase year-over-year. The company experienced significant growth in U.S. system placements and handpiece sales, reflecting strong demand for its HYDROS Robotic System. Despite a slight increase in net loss, the CEO remains optimistic about the company's growth potential and the adoption of Aquablation therapy.
Read more →PRCTPROCEPT BioRobotics to Report Third Quarter 2025 Financial Results on November 4, 2025
PROCEPT BioRobotics is scheduled to report its third quarter 2025 financial results on November 4, 2025. Following the release, management will host a conference call at 4:30 p.m. Eastern Time to discuss the results. The company continues to focus on advancing urological treatments with its robotic systems, including the innovative AQUABEAM and HYDROS technologies designed for BPH treatment.
Read more →PRCT▼ -5%on this news· ran to -19% by day 3
PROCEPT BioRobotics Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
PROCEPT BioRobotics reported strong financial results for Q2 2025, showcasing a 48% year-over-year increase in total revenue, driven primarily by robust demand for its robotic systems and consumables. Increased revenue guidance for the full year now stands at $325.5 million, reflecting a 45% growth expectation. Despite these positive developments, the company recorded a net loss of $19.6 million and a rise in operating expenses. The appointment of Larry Wood as CEO is anticipated to enhance company leadership as they focus on expanding the market share of Aquablation therapy.
Read more →About PROCEPT BioRobotics Corporation
Headquarters150 BAYTECH DRIVE, SAN JOSE, CA, 95134
BIOPHARMAWATCH ELITE PLUS
Trade the next PRCT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime